Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Basik

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Annals of Surgical Oncology|April 9, 2026
ASO Visual Abstract: Impact of Ethnicity on the Uptake of Risk-Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in CanadaSarah Mashal, Amel Melanson, Carla Apostolova, et al.
BMC Cancer|November 19, 2008
Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumorsLaure Voisin, Catherine Julien, Stéphanie Duhamel, et al.
Critical Reviews in Oncology/Hematology|May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyMartine T E Puts, Johanne Monette, Veronique Girre, et al.
Annals of Surgical Oncology|February 7, 2026
Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose TamoxifenNatasha J Stonebanks Cuillerier, Hamda Almarzooqi, Victor Villareal-Corpuz, et al.
Annals of Surgical Oncology|March 13, 2026
ASO Visual Abstract: Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose TamoxifenNatasha J Stonebanks Cuillerier, Hamda Almarzooqi, Victor Villareal Corpuz, et al.
Annals of Surgical Oncology|March 11, 2026
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in CanadaSarah Mashal, Amel Melanson, Carla Apostolova, et al.
Familial Cancer|April 28, 2026
Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomyAmel Melanson, Marya Alsuhaibani, Alex Viezel-Mathieu, et al.
Genome Research|October 4, 2003
RNAi microarray analysis in cultured mammalian cellsSpyro Mousses, Natasha J Caplen, Robert Cornelison, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 18, 2024
Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapyCarla Apostolova, Amina Ferroum, Basmah Alhassan, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Annals of Surgical Oncology|April 9, 2026
ASO Visual Abstract: Impact of Ethnicity on the Uptake of Risk-Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in CanadaSarah Mashal, Amel Melanson, Carla Apostolova, et al.
BMC Cancer|November 19, 2008
Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumorsLaure Voisin, Catherine Julien, Stéphanie Duhamel, et al.
Critical Reviews in Oncology/Hematology|May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyMartine T E Puts, Johanne Monette, Veronique Girre, et al.
Annals of Surgical Oncology|February 7, 2026
Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose TamoxifenNatasha J Stonebanks Cuillerier, Hamda Almarzooqi, Victor Villareal-Corpuz, et al.
Annals of Surgical Oncology|March 13, 2026
ASO Visual Abstract: Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose TamoxifenNatasha J Stonebanks Cuillerier, Hamda Almarzooqi, Victor Villareal Corpuz, et al.
Annals of Surgical Oncology|March 11, 2026
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in CanadaSarah Mashal, Amel Melanson, Carla Apostolova, et al.
Familial Cancer|April 28, 2026
Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomyAmel Melanson, Marya Alsuhaibani, Alex Viezel-Mathieu, et al.
Genome Research|October 4, 2003
RNAi microarray analysis in cultured mammalian cellsSpyro Mousses, Natasha J Caplen, Robert Cornelison, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 18, 2024
Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapyCarla Apostolova, Amina Ferroum, Basmah Alhassan, et al.
Current Oncology (Toronto, Ont.)|January 24, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single CentreAnna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, et al.
Pageof 13